SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

BARR PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware		1-9860		42-1612474
(State or other jurisdiction		(Commission		(IRS Employer
of incorporation)		File Number)		Identification No.)
400 Chestnut Ridge Road, Woodcliff Lake, NJ				07677
(Address of principal executive offices)				(Zip code)

(201) 930-3300

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 7.01 – Regulation FD Disclosure

     On August 14, 2006, Barr Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that its Duramed Pharmaceuticals subsidiary and Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) have entered into a Product Acquisition Agreement for ADDERALL^® tablets (immediate-release mixed amphetamine salts) and a Product Development Agreement for six proprietary products. The press release also announced that the Company’s Barr Laboratories subsidiary and two Shire subsidiaries have entered into a Settlement and License Agreement relating to the resolution of two pending patent cases involving Shire’s ADDERALL XR^®. The agreements will be submitted to the United States Federal Trade Commission, as required by law, and will become effective upon the entry by the applicable courts of consent judgments in the two pending cases.

     A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibits

99.1		Barr Pharmaceuticals, Inc. August 14, 2006 press release

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.